Search Results - "Milad, Mark A"

Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India by Jobe, Alan H., Milad, Mark A., Peppard, Thomas, Jusko, William J.

“…High‐dose betamethasone and dexamethasone are standard of care treatments for women at risk of preterm delivery to improve neonatal respiratory and mortality…”
Get full text

Estimating fetal exposure to the P‐gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome by Anoshchenko, Olena, Milad, Mark A., Unadkat, Jashvant D.

“…We have previously developed a maternal‐fetal physiologically‐based pharmacokinetic (m‐f PBPK) model to dynamically predict (and verify) fetal‐maternal…”
Get full text

Minimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids by Krzyzanski, Wojciech, Milad, Mark A., Jobe, Alan H., Jusko, William J.

“…Minimal physiologically‐based pharmacokinetic (mPBPK) models are an alternative to full physiologically‐based pharmacokinetic (PBPK) models as they offer…”
Get full text

Evaluation of Maternal Drug Exposure Following the Administration of Antenatal Corticosteroids During Late Pregnancy Using Physiologically‐Based Pharmacokinetic Modeling by Ke, Alice Ban, Milad, Mark A.

“…Betamethasone and dexamethasone are the most widely studied antenatal corticosteroids (ACS) administered to pregnant women, just prior to the birth of a…”
Get full text

Application of exposure bracketing to streamline the development of contraceptive products by Brown, Joshua, Goodrow, Tamra, Hartman, Dan, Hay, Justin L., Hershberger, Kevin, Hershenson, Susan, McNair, Douglas, Matthews, Bethany, Milad, Mark A., Schmidt, Stephan, Vogelsong, Kirsten M, Zhao, Ping

“…Developing new long-acting products of well-characterized contraceptive drugs is one way to address some of the reasons for unmet need for modern methods of…”
Get full text

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus by Gutierrez, Maria J, Rosenberg, Noah L, MacDougall, Diane E, Hanselman, Jeffrey C, Margulies, Janice R, Strange, Poul, Milad, Mark A, McBride, Scott J, Newton, Roger S

“…OBJECTIVE—8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (ETC-1002) is a small molecule with a unique mechanism of action shown in nonclinical studies to…”
Get full text

Low-dose antenatal betamethasone treatment achieves preterm lung maturation equivalent to that of the World Health Organization dexamethasone regimen but with reduced endocrine disruption in a sheep model of pregnancy by Usuda, Haruo, Fee, Erin L., Carter, Sean, Furfaro, Lucy, Takahashi, Tsukasa, Takahashi, Yuki, Newnham, John P., Milad, Mark A., Saito, Masatoshi, Jobe, Alan H., Kemp, Matthew W.

“…The intramuscular administration of antenatal steroids to women at risk of preterm delivery achieves high maternal and fetal plasma steroid concentrations,…”
Get full text

Pharmacokinetics of levonorgestrel and etonogestrel in rat or minipig following intravenous, subcutaneous, or intradermal administration by Ko, Paul J., Milad, Mark A., Radulovic, Louis L., Gibson, Don M.

“…The objective of these studies was to determine the pharmacokinetics of levonorgestrel and etonogestrel in Sprague-Dawley rat or Göttingen minipig following…”
Get full text

Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor by Sahi, Jasminder, Milad, Mark A, Zheng, Xianxian, Rose, Kelly A, Wang, Hongbing, Stilgenbauer, Linda, Gilbert, Darryl, Jolley, Summer, Stern, Ralph H, LeCluyse, Edward L

“…In vitro and clinical studies were conducted to characterize the potential of avasimibe, an acyl-CoA/cholesterol acyltransferase inhibitor to cause drug-drug…”
Get more information

One percent of the clinical dose used for antenatal steroid therapy is sufficient to induce lung maturation when administered directly to the preterm ovine fetus by Fee, Erin L, Takahashi, Tsukasa, Takahashi, Yuki, Carter, Sean, Furfaro, Lucy, Clarke, Michael W, Milad, Mark A, Usuda, Haruo, Newnham, John P, Saito, Masatoshi, Jobe, Alan H, Kemp, Matthew W

“…Antenatal steroids (ANSs) are routinely administered to women judged to be at imminent risk of preterm delivery. Their principal benefit is precocious…”
Get more information

Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women by Krzyzanski, Wojciech, Milad, Mark A., Jobe, Alan H., Peppard, Thomas, Bies, Robert R., Jusko, William J.

“…Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian…”
Get full text

Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women by Krzyzanski, Wojciech, Milad, Mark A., Jobe, Alan H., Peppard, Thomas, Bies, Robert R., Jusko, William J.

“…Population pharmacokinetic/pharmacodynamic (PK/PD) analysis was performed for extensive data for differing dosage forms and routes for dexamethasone (DEX) and…”
Get full text

Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics by Lew, K H, Ludwig, E A, Milad, M A, Donovan, K, Middleton, Jr, E, Ferry, J J, Jusko, W J

“…The pharmacokinetics and selected pharmacodynamic responses to methylprednisolone were investigated in six men and six premenopausal women after a dose of 0.6…”
Get more information

EFFECTS OF AVASIMIBE ON CYTOCHROME P450 2C9 EXPRESSION IN VITRO AND IN VIVO by SAHI, Jasminder, STERN, Ralph H, LECLUYSE, Edward L, MILAD, Mark A, ROSE, Kelly A, GIBSON, Gordon, XIANXIAN ZHENG, STILGENBAUER, Linda, SADAGOPAN, Nalini, JOLLEY, Summer, GILBERT, Darryl

“…Avasimibe, an acyl-CoA:cholesterol acyltransferase inhibitor, has been previously shown to be a potent inducer of CYP3A4 and multiple drug resistance protein…”
Get full text

2.22 Safety, Efficacy, and Exposure-Response of Nnz-2591, a Synthetic Analog of Cyclic Glycine-Proline (cGP), an IGF-1 Metabolite, for the Treatment of Phelan-Mcdermid Syndrome in Children and Adolescents by Wada, Russell, Kastrissios, Helen, Milad, Mark A., Ghomlaghi, Milad, Jones, Nancy E., Squires, Liza, Glass, Larry

Get full text

Preclinical safety evaluation of avasimibe in beagle dogs : An ACAT inhibitor with minimal adrenal effects by ROBERTSON, Donald G, BREIDER, Michael A, MILAD, Mark A

“…Avasimibe, a novel inhibitor of acyl coenzyme A:cholesterol acyltransferase (ACAT), is currently being developed as an antiatherosclerotic agent. The…”
Get full text

Pharmacodynamic interpretation of adrenocorticotropin stimulation tests by Milad, M A, Jusko, W J

“…To report a pharmacodynamic model that describes increases in cortisol concentrations during administration of an adrenocorticotropin (ACTH) infusion, taking…”
Get more information

Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking by Milad, M A, Ludwig, E A, Anné, S, Middleton, Jr, E, Jusko, W J

“…The circadian pattern of the immune system correlates with that of circulating T-helper cells and inversely with cortisol concentrations. Corticosteroids, both…”
Get more information